NCT02681172View on ClinicalTrials.gov

Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD

PHASE4CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

November 30, 2016

Conditions
Alzheimer's Disease (AD)
Interventions
DRUG

Neuraceq (florbetaben 18F)

Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.

PROCEDURE

PET

A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.

Trial Locations (1)

13385

Coordinating center (Hôpital de La Timone) and 18 associated centers in France, Marseille

All Listed Sponsors
lead

Piramal Imaging Limited

INDUSTRY

NCT02681172 - Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD | Biotech Hunter | Biotech Hunter